Inclusion Criteria:  Provision of signed and dated informed consent form from a participant or legally authorized representative (LAR); Male or female, >18 years old; Hospitalized participants with a laboratory diagnosis of COVID-19 infection Evidence of persistent AKI as defined by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines (Table 3); Willing to adhere to the study intervention regimen;  Exclusion Criteria:  Hypersensitivity to nicotinamide riboside (NR); Pregnant or lactating women confirmed with positive laboratory pregnancy tests as per local requirements; eGFR <15 mL/min/1.73 m2 as per the Chronic Kidney Disease Epidemiology Collaboration equation at admission lab; Maintenance renal replacement therapy or initiation of renal replacement therapy before randomization Currently on NR or nicotinamide or vitamin B3 (niacin) supplementation (multivitamins are allowed); Concomitant cirrhosis of liver or acute liver failure; Any medical history or condition that might, in the opinion of the attending physician, put the participant at significant risk if he/she were to participate in the trial; Individuals with kidney transplant; Individuals with blood platelet count <100,000/microL